Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Next Previous
Trial Profile

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Ibrutinib (Primary) ; Loncastuximab tesirine (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics

    • Most Recent Events

    • 10 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
    • 20 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 03 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top